Gateway Investment Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $873K | Buy |
2,900
+649
| +29% | +$196K | 0.01% | 465 |
|
|
2026
Q1 | $745K | Sell |
2,251
-2,890
| -56% | -$983K | 0.01% | 398 |
|
|
2025
Q4 | $2.04M | Hold |
5,141
| – | – | 0.02% | 282 |
|
|
2025
Q3 | $2.34M | Sell |
5,141
-748
| -13% | -$305K | 0.02% | 256 |
|
|
2025
Q2 | $1.92M | Sell |
5,889
-651
| -10% | -$180K | 0.02% | 256 |
|
|
2025
Q1 | $1.77M | Sell |
6,540
-843
| -11% | -$217K | 0.02% | 267 |
|
|
2024
Q4 | $1.74M | Buy |
7,383
+1,222
| +20% | +$321K | 0.02% | 269 |
|
|
2024
Q3 | $1.69M | Sell |
6,161
-516
| -8% | -$134K | 0.02% | 272 |
|
|
2024
Q2 | $1.62M | Sell |
6,677
-12,360
| -65% | -$1.95M | 0.02% | 270 |
|
|
2024
Q1 | $2.85M | Buy |
19,037
+6
| +0% | +$1K | 0.03% | 240 |
|
|
2023
Q4 | $3.64M | Buy |
19,031
+5,080
| +36% | +$865K | 0.04% | 237 |
|
|
2023
Q3 | $2.47M | Buy |
13,951
+2,393
| +21% | +$457K | 0.03% | 258 |
|
|
2023
Q2 | $2.2M | Buy |
11,558
+486
| +4% | +$96.4K | 0.03% | 266 |
|
|
2023
Q1 | $2.22M | Sell |
11,072
-129
| -1% | -$27.1K | 0.03% | 282 |
|
|
2022
Q4 | $2.66M | Buy |
11,201
+260
| +2% | +$55.5K | 0.03% | 283 |
|
|
2022
Q3 | $2.19M | Sell |
10,941
-15,324
| -58% | -$2.92M | 0.03% | 304 |
|
|
2022
Q2 | $3.83M | Buy |
26,265
+26
| +0.1% | +$3.69K | 0.04% | 257 |
|
|
2022
Q1 | $4.29M | Buy |
26,239
+21,671
| +474% | +$3.3M | 0.04% | 258 |
|
|
2021
Q4 | $775K | Sell |
4,568
-6
| -0.1% | -$1.11K | 0.01% | 365 |
|
|
2021
Q3 | $864K | Buy |
4,574
+330
| +8% | +$61.9K | 0.01% | 362 |
|
|
2021
Q2 | $719K | Hold |
4,244
| – | – | 0.01% | 387 |
|
|
2021
Q1 | $599K | Buy |
4,244
+10
| +0.2% | +$1.5K | 0.01% | 399 |
|
|
2020
Q4 | $550K | Buy |
4,234
+77
| +2% | +$10.3K | 0.01% | 399 |
|
|
2020
Q3 | $605K | Sell |
4,157
-62
| -1% | -$8.81K | 0.01% | 380 |
|
|
2020
Q2 | $625K | Hold |
4,219
| – | – | 0.01% | 398 |
|
|
2020
Q1 | $459K | Sell |
4,219
-1
| -0% | -$115 | 0.01% | 415 |
|
|
2019
Q4 | $486K | Sell |
4,220
-97
| -2% | -$9.67K | ﹤0.01% | 442 |
|
|
2019
Q3 | $347K | Sell |
4,317
-3
| -0.1% | -$237 | ﹤0.01% | 489 |
|
|
2019
Q2 | $313K | Hold |
4,320
| – | – | ﹤0.01% | 625 |
|
|
2019
Q1 | $404K | Sell |
4,320
-211
| -5% | -$17.6K | ﹤0.01% | 595 |
|
|
2018
Q4 | $330K | Buy |
4,531
+667
| +17% | +$51.3K | ﹤0.01% | 616 |
|
|
2018
Q3 | $338K | Hold |
3,864
| – | – | ﹤0.01% | 620 |
|
|
2018
Q2 | $381K | Sell |
3,864
-37
| -0.9% | -$3.67K | ﹤0.01% | 616 |
|
|
2018
Q1 | $465K | Buy |
3,901
+330
| +9% | +$42.5K | ﹤0.01% | 602 |
|
|
2017
Q4 | $454K | Buy |
+3,571
| New | +$449K | ﹤0.01% | 614 |
|
Other funds holding ALNY
Gateway Investment Advisers's ALNY Position: Q2 2026 in Review
Gateway Investment Advisers increased its Alnylam Pharmaceuticals (ALNY) stake by 29% in Q2 2026, buying an estimated $196K and bringing the position to 2,900 shares worth $873K. The position accounts for 0.01% of the portfolio, ranked #465.
Gateway Investment Advisers first reported a position in ALNY in Q4 2017 and has held it in 35 quarters since. The position peaked at $4.29M in Q1 2022. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Gateway Investment Advisers held 2,900 shares of Alnylam Pharmaceuticals worth $873K as of Q2 2026.
- Gateway Investment Advisers bought 649 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $196K.
- Alnylam Pharmaceuticals made up 0.01% of Gateway Investment Advisers's portfolio in Q2 2026, its #465 holding.
- Gateway Investment Advisers first reported a position in Alnylam Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
- Gateway Investment Advisers's Alnylam Pharmaceuticals position peaked at $4.29M in Q1 2022.
- 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Gateway Investment Advisers's 13F filing for Q2 2026, filed 20 Jul 2026.